Axovant Sciences, a late stage biotech developing an Alzheimer's therapy acquired from GlaxoSmithKline, filed on Monday with the SEC to raise up to $173 million in an initial public offering.
The Hamilton, Bermuda-based company, which was formed in 2014, plans to list on the NYSE under the symbol AXON. Axovant Sciences initially filed confidentially on 3/24/2015. Jefferies, Evercore Partners and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
